HilleVax, Inc. Announces Executive Team Restructuring

HilleVax, Inc (HLVX) has released an update to notify the public and investors about its officers.

HilleVax, Inc. has appointed Sean McLoughlin as its new Chief Operating Officer, effective January 16, 2024, with Dr. Aditya Kohli transitioning to Chief Business Officer on February 19, 2024, as David Socks departs the role. McLoughlin, a former employee of GlaxoSmithKline with extensive experience in the vaccine business, holds a B.Sc. in Accounting, an M.B.A., and a Wharton School executive education certificate. His compensation package includes a $450,000 base salary, potential bonuses, a $200,000 sign-on bonus, and eligibility for severance benefits under certain conditions, including options for 250,000 shares of the company’s common stock that vest over four years.

For further insights into HLVX corporate activity, check out TipRanks’ Insiders Trading Activity page.